Legacy facilities are getting tough to unload

In contrast to the past, it now takes more than a bargain price to attract a buyer for a redundant pharma manufacturing plant. A strong strategic rationale and revenue stream need to be in the mix for the buyer to achieve viability. Executives are walking away from bargain-basement pricing because of missing long-term economics and strategic rationale. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.